Testosterone Replacement Therapy and Cardiovascular Disease: Balancing Safety and Risks in Hypogonadal Men

Area of Science:

• Cardiovascular Medicine
• Endocrinology

Background:

• Hypogonadism is linked to increased mortality in men with cardiovascular disease (CVD).
• Previous studies on testosterone replacement therapy (TRT) and cardiovascular events have yielded conflicting results.
• TRT aims to restore physiological testosterone levels.

Purpose of the Study:

• To analyze the association between testosterone replacement therapy (TRT) and adverse cardiovascular (CV) events.
• To evaluate the safety and potential benefits of TRT in men with hypogonadism and CVD.

Main Methods:

• Review of existing literature on TRT and CV outcomes.
• Critical analysis of studies suggesting a link between TRT and CV events, noting methodological flaws.
• Synthesis of evidence regarding TRT's impact on CVD risk factors and patient outcomes.

Main Results:

• Some studies suggest a link between TRT and CV events, but these often have methodological limitations.
• Numerous studies indicate a reduction in CV events with TRT.
• TRT in hypogonadal men can improve CVD risk factors, reduce QT interval prolongation, benefit heart failure patients, and slow atherosclerosis progression.

Conclusions:

• TRT to achieve physiological testosterone concentrations is not a threat to CV health.
• TRT in hypogonadal men demonstrates a cardioprotective effect.
• TRT may be beneficial for cardiovascular health in appropriately selected hypogonadal men.